Tissue Regenix Group (LON:TRX) has appointed a new chief financial officer.

The regenerative medical devices specialist said Mike Barker will join the board with immediate effect having held the role on an interim basis since the start of the year.

A chartered accountant, Barker spent 10 years in corporate finance advisory, working on private equity transactions, before setting up his own consultancy that counselled small and mid-sized companies.

He has also worked closely with the management team of Quantum Pharma, the manufacturer bought by Clinigen two years ago, and held the position of corporate development director there.

Chairman John Samuel said of Barker: “His experience in AIM-listed businesses and contribution to strategic planning will augment and strengthen our management and executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products.”